Premier Alternatives

ViTToria Biotherapeutics

Philadelphia, PA · Founded 2021 · Privately Held (backing)

Operator of a T-cell therapeutics company intended to offer a therapeutic pipeline targeting clinical needs in oncology and autoimmune disease. ViTToria Biotherapeutics is based in Philadelphia, PA and was founded in 2021. It was valued at $30 million at its early-stage round in Nov 2024, the last priced event on record. It has raised $49.9 million across 1 recorded round; the latest was an $8.7 million early-stage round in Jul 2021.

PMV mark · valuation
$30.0M
Oct 2026
Priced at
its early-stage round
Nov 2024
Total raised
$49.9M
Last round
Early Stage VC
Jul 2021

ViTToria Biotherapeutics key facts

as of Oct 2026
  • Operator of a T-cell therapeutics company intended to offer a therapeutic pipeline targeting clinical needs in oncology and autoimmune disease.
  • ViTToria Biotherapeutics is valued at approximately $30.0M as of Oct 2026, set at its early-stage round, Nov 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $49.9M across 1 recorded rounds; the latest was Early Stage VC ($8.7M) in Jul 2021.
  • Notable investors include KB Investment, Ben Franklin Technology Partners of Southeastern Pennsylvania, SV Health Investors, BioAdvance Capital (Conshohocken), NYBC Ventures — 15 tracked in total.
  • ViTToria Biotherapeutics has filed 1 Form D with the SEC, most recently Dec 2021 ($8.7M sold to 11 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$30.0M

Valued at $30.0M at its early-stage round, Nov 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of ViTToria Biotherapeutics with a free account
  • ·The complete investor list: 15 names
  • ·Watch ViTToria Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ViTToria Biotherapeutics funding rounds

1 rounds
Jul 2021Early Stage VC$8.7MSEC filing▮
Full funding history →

ViTToria Biotherapeutics valuation

ViTToria Biotherapeutics was valued at $30 million at its early-stage round in Nov 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has ViTToria Biotherapeutics raised?

ViTToria Biotherapeutics has raised $49.9 million in total; 1 of its rounds is on record. The largest on record was an $8.7 million early-stage round in Jul 2021.

ViTToria Biotherapeutics has filed 1 Form D with the SEC, most recently in Dec 2021 ($8.7 million sold to 11 investors).

ViTToria Biotherapeutics investors

15 investors are on record for ViTToria Biotherapeutics, including KB Investment, Ben Franklin Technology Partners of Southeastern Pennsylvania, SV Health Investors and BioAdvance Capital (Conshohocken). The early-stage round in Jul 2021 drew 11 investors.

About ViTToria Biotherapeutics

Operator of a T-cell therapeutics company intended to offer a therapeutic pipeline targeting clinical needs in oncology and autoimmune disease. The company's technology improves efficacy, enhances safety, and expands the utility of cell-based therapeutics by lowering dosing requirements, easing preconditioning regimens, reducing manufacturing failures, and shortening vein-to-vein times, enabling medical practitioners to improve patient outcomes.

Sector
Healthcare
HQ
Philadelphia, PA, United States
Founded
2021
Employees
12
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.